Dr. Mitchell Horwitz
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Rush Medical College of Rush University (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 86
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Rush Medical College of Rush University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Infectious Disease Physician primary
- Hematology & Oncology Physician
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 243
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 140 | 24 |
| Established patient office or other outpatient visit, 40-54 minutes | 78 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Durham, NC | 47 |
| Jakafi (ruxolitinib phosphate) | 29 |
| Hydrocortisone Other prescribers in Durham, NC | 18 |
| Montelukast Sodium Other prescribers in Durham, NC | 16 |
| Tasigna (nilotinib hcl) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 24 payments worth $21,403 in total to this clinician.
| Gamida Cell Inc. | $12,279 |
|---|---|
| Incyte Corporation | $7,858 |
| Vertex Pharmaceuticals Incorporated | $941 |
| National Marrow Donor Program | $325 |
| Consulting Fee | $19,010 |
|---|---|
| Travel and Lodging | $1,748 |
| Food and Beverage | $645 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gamida Cell Inc. Aug 11, 2025 | Consulting Fee OMISIRGE · ONCOLOGY | $12,160 |
| Incyte Corporation May 8, 2025 | Consulting Fee Niktimvo · Oncology | $6,850 |
| Incyte Corporation Apr 24, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $482 |
| Vertex Pharmaceuticals Incorporated Jul 27, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $417 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $348 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $291 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $93.75 |
| Gamida Cell Inc. Aug 11, 2025 | Travel and Lodging OMISIRGE · ONCOLOGY · travel to CHICAGO, IL | $75.27 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $42.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $257,028 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2)
Kite Pharma, Inc. - A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Alexion Pharmaceuticals, Inc. - A study to evaluate vimseltinib in adults with active chronic graft-versus-host disease (cgvhd)
Deciphera Pharmaceuticals Inc. - Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Gamida Cell Inc. · Completed · NCT04260698 - The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Csl Behring · Terminated · NCT03805789 - A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.